



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/40, 31/55, 31/445, C07D 209/08, 209/12, 223/04, 401/14</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/38692</p> <p>(43) International Publication Date: 23 October 1997 (23.10.97)</p>								
<p>(21) International Application Number: PCT/US97/05996</p> <p>(22) International Filing Date: 11 April 1997 (11.04.97)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/015,318</td> <td>12 April 1996 (12.04.96)</td> <td>US</td> </tr> <tr> <td>60/015,329</td> <td>12 April 1996 (12.04.96)</td> <td>US</td> </tr> <tr> <td>60/015,331</td> <td>12 April 1996 (12.04.96)</td> <td>US</td> </tr> </table> <p>(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(72) Inventors: HIPSKIND, Philip, Arthur; 3660 South Farmstone Circle, New Palestine, IN 46163 (US). LOBB, Karen, Lynn; 5625 East Lowell Avenue, Indianapolis, IN 46219 (US). PHEBUS, Lee, Alan; 1744 West 1000 North, Fountaintown, IN 46130 (US). SCHAUS, John, Mehnert; 135 Raintree Drive, Zionsville, IN 46077 (US).</p> <p>(74) Agents: GAYLO, Paul, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p>	60/015,318	12 April 1996 (12.04.96)	US	60/015,329	12 April 1996 (12.04.96)	US	60/015,331	12 April 1996 (12.04.96)	US	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
60/015,318	12 April 1996 (12.04.96)	US								
60/015,329	12 April 1996 (12.04.96)	US								
60/015,331	12 April 1996 (12.04.96)	US								
<p>(54) Title: BISINDOLES FOR TREATING PAIN OR NOCICEPTION</p>										
<p>(57) Abstract</p> <p>This invention provides a series of bisindoles having activity as both a tachykinin receptor antagonist and a serotonin agonist. This invention provides methods of using these bisindoles to treat migraine, pain or nociception, allergic rhinitis, the common cold, and a variety of psychiatric disorders.</p>										

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Title**BISINDOLES FOR TREATING PAIN OR NOCICEPTION**

5

Background of the Invention

Since the discovery of serotonin (5-hydroxytryptamine, 5-HT) over four decades ago, the cumulative results of many diverse studies have indicated that serotonin plays a significant role in the functioning of the mammalian body, both in the central nervous system and in peripheral systems as well. Morphological studies of the central nervous system have shown that serotonergic neurons, which originate in the brain stem, form a very diffuse system that projects to most areas of the brain and spinal cord. R.A. O'Brien, Serotonin in Mental Abnormalities, 1:41 (1978); H.W.M. Steinbusch, HANDBOOK OF CHEMICAL NEUROANATOMY, Volume 3, Part II, 68 (1984); N.E. Anden, et al., Acta Physiologica Scandinavia, 67:313 (1966). These studies have been complemented by biochemical evidence that indicates large concentrations of 5-HT exist in the brain and spinal cord. H.W.M. Steinbusch, supra.

With such a diffuse system, it is not surprising that 5-HT has been implicated as being involved in the expression of a number of behaviors, physiological responses, and diseases which originate in the central nervous system. These include such diverse areas as sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, schizophrenia, and other bodily states. R.W. Fuller, BIOLOGY OF SEROTONERGIC TRANSMISSION, 221 (1982); D.J. Boullin, SEROTONIN IN MENTAL ABNORMALITIES 1:316 (1978); J. Barchas, et al., Serotonin and Behavior, (1973).

Serotonin plays an important role in peripheral systems as well. For example, approximately 90% of the body's serotonin is synthesized in the gastrointestinal system, and serotonin has been found to mediate a variety of contractile, secretory, and electrophysiologic effects in this system. Serotonin may be taken up by the platelets and, upon platelet aggregation, be released such that the cardiovascular system

35

- 2 -

provides another example of a peripheral network that is very sensitive to serotonin. Given the broad distribution of serotonin within the body, it is understandable that tremendous interest in drugs that affect serotonergic systems exists. In particular, receptor-specific agonists and antagonists are of interest for the treatment of a wide range of disorders, including anxiety, depression, hypertension, migraine, compulsive disorders, schizophrenia, autism, neurodegenerative disorders, such as Alzheimer's disease, Parkinsonism, and Huntington's chorea, and cancer chemotherapy-induced vomiting. M.D. Gershon, et al., THE PERIPHERAL ACTIONS OF 5-HYDROXYTRYPTAMINE, 246 (1989); P.R. Saxena, et al., Journal of Cardiovascular Pharmacology, 15:Supplement 7 (1990).

Serotonin produces its effects on cellular physiology by binding to specialized receptors on the cell surface. It is now recognized that multiple types of receptors exist for many neurotransmitters and hormones, including serotonin. The existence of multiple, structurally distinct serotonin receptors has provided the possibility that subtype-selective pharmacological agents can be produced. The development of such compounds could result in new and increasingly selective therapeutic agents with fewer side effects, since activation of individual receptor subtypes may function to affect specific actions of the different parts of the central and/or peripheral serotonergic systems.

An example of such specificity can be demonstrated by using the vascular system as an example. In certain blood vessels, stimulation of 5-HT₁-like receptors on the endothelial cells produces vasodilation while stimulation of 5-HT₂ receptors on the smooth muscle cells produces vasoconstriction.

Currently, the major classes of serotonin receptors (5-HT₁, 5-HT₂, 5-HT₃, 5-HT₄, 5-HT₅, 5-HT₆, and 5-HT₇) contain some fourteen to eighteen separate receptors that have been formally classified based on their pharmacological or structural differences. [For a review of the pharmacological effects and clinical implications of the various 5-HT receptor types, see Glennon, et al., Neuroscience and Behavioral Reviews, 14:35 (1990).]

Tachykinins are a family of peptides which share a common amidated carboxy terminal sequence. Substance P was the first peptide of

- 3 -

this family to be isolated, although its purification and the determination of its primary sequence did not occur until the early 1970's.

Between 1983 and 1984 several groups reported the isolation of two novel mammalian tachykinins, now termed neurokinin A (also
5 known as substance K, neuromedin L, and neurokinin α), and neurokinin B (also known as neuromedin K and neurokinin β). See, J.E. Maggio, Peptides, 6 (Supplement 3):237-243 (1985) for a review of these discoveries.

Tachykinins are widely distributed in both the central and
10 peripheral nervous systems, are released from nerves, and exert a variety of biological actions, which, in most cases, depend upon activation of specific receptors expressed on the membrane of target cells. Tachykinins are also produced by a number of non-neural tissues.

The mammalian tachykinins substance P, neurokinin A, and
15 neurokinin B act through three major receptor subtypes, denoted as NK-1, NK-2, and NK-3, respectively. These receptors are present in a variety of organs.

Substance P is believed inter alia to be involved in the neurotransmission of pain sensations, including the pain associated with
20 migraine headaches and with arthritis. These peptides have also been implicated in gastrointestinal disorders and diseases of the gastrointestinal tract such as inflammatory bowel disease. Tachykinins have also been implicated as playing a role in numerous other maladies, as discussed infra.

Tachykinins play a major role in mediating the sensation and
25 transmission of pain or nociception, especially migraine headaches. see, e.g., S.L. Shephard, et al., British Journal of Pharmacology, 108:11-20 (1993); S.M. Moussaoui, et al., European Journal of Pharmacology, 238:421-424 (1993); and W.S. Lee, et al., British Journal of Pharmacology,
30 112:920-924 (1994).

In view of the wide number of clinical maladies associated with an excess of tachykinins, the development of tachykinin receptor antagonists will serve to control these clinical conditions. The earliest tachykinin receptor antagonists were peptide derivatives. These

- 4 -

antagonists proved to be of limited pharmaceutical utility because of their metabolic instability.

Recent publications have described novel classes of non-peptidyl tachykinin receptor antagonists which generally have greater oral bioavailability and metabolic stability than the earlier classes of tachykinin receptor antagonists. Examples of such newer non-peptidyl tachykinin receptor antagonists are found in United States Patent 5,491,140, issued February 13, 1996; United States Patent 5,328,927, issued July 12, 1994; United States Patent 5,360,820, issued November 1, 1994; United States Patent 5,344,830, issued September 6, 1994; United States Patent 5,331,089, issued July 19, 1994; European Patent Publication 591,040 A1, published April 6, 1994; Patent Cooperation Treaty publication WO 94/01402, published January 20, 1994; Patent Cooperation Treaty publication WO 94/04494, published March 3, 1994; Patent Cooperation Treaty publication WO 93/011609, published January 21, 1993; Canadian Patent Application 2154116, published January 23, 1996; European Patent Publication 693,489, published January 24, 1996; and Canadian Patent Application 2151116, published December 11, 1995.


United States Patent Application 08/318,391, filed October 5, 1994, describes a synergistic effect on the combination of a serotonin agonist and a tachykinin receptor antagonist in treating migraine. United States Patent Application 08/387,056, filed February 10, 1995, describes a synergistic effect on the combination of a serotonin agonist and a tachykinin receptor antagonist in treating a variety of psychiatric disorders. United States Patent Application 08/408,238, filed March 22, 1995, describes a synergistic effect on the combination of a serotonin agonist and a tachykinin receptor antagonist in treating a variety of types of pain and nociception. United States Patent Application 60/000074, filed June 8, 1995, describes a synergistic effect on the combination of a serotonin agonist and a tachykinin receptor antagonist in treating the common cold or allergic rhinitis.

Because of the current dissatisfaction of the currently marketed treatments for treating the above-described indications within the affected population, there exists a need for a more efficacious and safe treatment.

Summary of the Invention

This invention provides the compounds of Formula I

5



wherein:

10

R^1 , R^2 , and R^3 are independently hydrogen, halo, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, nitro, trifluoromethyl, or C_1 - C_6 alkyl;

15

A is $-CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$;

R^a is hydrogen or hydroxy, and R^b is hydrogen, or R^a and R^b are taken together to form a bond;

20

R^4 and R^5 are independently taken from the group consisting of halo, trifluoromethyl, hydrogen, C_1 - C_6 alkoxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 alkylamino, hydroxy, cyano, C_2 - C_7 alkanoyl, C_2 - C_7 alkanoyloxy, benzamido, phenoxy,

- 6 -

carboxamido, hydroxy, benzyloxy, phenyl(C₂-C₇ alkanoyl)-,
C₁-C₆ phenyl(C₂-C₇ carbamoyl)-,

5 said benzamido, phenoxy, benzyloxy, phenyl(C₂-
C₇ alkanoyl)-, and phenyl(C₂-C₇ carbamoyl)-
being optionally substituted with one or more
groups selected from the group consisting of
halo, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy,
cyano, hydroxy, amino and nitro;

10

or a pharmaceutically acceptable salt or solvate thereof.

 This invention also provides methods for treating or
preventing a number of disorders characterized by their being affected, in
15 a synergistic manner, by a combination of a serotonin agonist and a
tachykinin receptor antagonist, which comprise administering to a
mammal in need thereof an effective amount of a compound of Formula I
or a pharmaceutically acceptable salt or solvate thereof. Among these
disorders are: pain or nociception; migraine; the common cold; allergic
20 rhinitis; or a psychiatric disorder selected from the group consisting of
panic disorder, panic attack, depression, anxiety, bulimia nervosa,
obsessive-compulsive disorder, premenstrual dysphoric disorder,
substance abuse, substance dependence, agoraphobia, post-traumatic
stress disorder, dementia of Alzheimer's type, social phobia, attention
25 deficit hyperactivity disorder, disruptive behavior disorder, intermittent
explosive disorder, borderline personality disorder, chronic fatigue
syndrome, premature ejaculation, and depression and behavioral
problems associated with head injury, mental retardation, and stroke.

30

 This invention also provides pharmaceutical formulations
which comprise a compound of Formula I, or a pharmaceutically
acceptable salt or solvate thereof, in combination with one or more
pharmaceutically acceptable carriers, diluents, or excipients therefor.

Detailed Description and Preferred Embodiments

The terms and abbreviations used in the instant examples have their normal meanings unless otherwise designated. For example
5 "°C" refers to degrees Celsius; "N" refers to normal or normality; "mmol" refers to millimole or millimoles; "g" refers to gram or grams; "ml" means milliliter or milliliters; "M" refers to molar or molarity; "MS" refers to mass spectrometry; "FDMS" refers to field desorption mass spectrometry; "UV" refers to ultraviolet spectroscopy; "IR" refers to infrared
10 spectroscopy; and "NMR" refers to nuclear magnetic resonance spectroscopy.

As used herein, the term "C₁-C₆ alkyl" refers to straight or branched, monovalent, saturated aliphatic chains of 1 to 6 carbon atoms and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl,
15 isobutyl, *t*-butyl, pentyl, isopentyl, and hexyl. The term "C₁-C₆ alkyl" includes within its definition the term "C₁-C₄ alkyl".

"Halo" represents chloro, fluoro, bromo or iodo.

"C₁-C₆ alkylthio" represents a straight or branched alkyl
20 chain having from one to six carbon atoms attached to a sulfur atom. Typical C₁-C₆ alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio and the like. The term "C₁-C₆ alkylthio" includes within its definition the term "C₁-C₄ alkylthio".

"C₁-C₆ alkylamino" represents a straight or branched
25 alkylamino chain having from one to six carbon atoms attached to an amino group. Typical C₁-C₆ alkyl-amino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, *sec*-butylamino and the like.

"C₁-C₆ alkoxy" represents a straight or branched alkyl chain
30 having from one to six carbon atoms attached to an oxygen atom. Typical C₁-C₆ alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, *t*-butoxy, pentoxy and the like. The term "C₁-C₆ alkoxy" includes within its definition the term "C₁-C₄ alkoxy".

"C₂-C₆ alkanoyl" represents a straight or branched alkyl
35 chain having from one to five carbon atoms attached through a carbonyl moiety. Typical C₂-C₆ alkanoyl groups include ethanoyl (also referred to


- 8 -

as acetyl), propanoyl, isopropanoyl, butanoyl, *t*-butanoyl, pentanoyl, hexanoyl, and the like.

“C₁-C₆ alkylene” refers to a straight or branched, divalent, saturated aliphatic chain of one to six carbon atoms and includes, but is not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, *t*-butylene, pentylene, isopentylene, hexylene, and the like.

The term “C₂-C₇ carbamoyl” as used herein refers to a moiety having one of the following two structures.

10



15

20

The term “heterocycle” represents a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated or unsaturated and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of nitrogen, oxygen or sulfur, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized and including a bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which affords a stable structure.

25

30

The term “amino-protecting group” as used in the specification refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the compound. Examples of such amino-protecting groups include formyl, trityl, phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl, and urethane-type blocking groups such as benzyloxycarbonyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl,

- 9 -

4-cyanobenzyloxycarbonyl, *t*-butoxycarbonyl,
1,1-diphenyleth-1-yloxycarbonyl, 1,1-diphenylprop-1-yloxycarbonyl,
2-phenylprop-2-yloxycarbonyl, 2-(*p*-toluyl)-prop-2-yloxycarbonyl,
cyclopentanyloxycarbonyl, 1-methylcyclopentanyloxycarbonyl,
5 cyclohexanyloxycarbonyl, 1-methylcyclohexanyloxycarbonyl,
2-methylcyclohexanyloxycarbonyl, 2-(4-toluylsulfonyl)-ethoxycarbonyl,
2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl,
fluorenylmethoxy-carbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl,
allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl,
10 5-benzisoxalylmethoxycarbonyl, 4-acetoxybenzyloxycarbonyl,
2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl,
cyclopropylmethoxycarbonyl, 4-(decyloxy)benzyloxycarbonyl,
isobornyloxycarbonyl, 1-piperidyloxycarbonyl and the like;
benzoylmethylsulfonyl group, 2-nitrophenylsulfenyl, diphenylphosphine
15 oxide and like amino-protecting groups. The species of amino-protecting
group employed is usually not critical so long as the derivatized amino
group is stable to the condition of subsequent reactions on other positions
of the intermediate molecule and can be selectively removed at the
appropriate point without disrupting the remainder of the molecule
20 including any other amino-protecting groups. Preferred amino-protecting
groups are trityl, *t*-butoxycarbonyl (*t*-BOC), allyloxycarbonyl and
benzyloxycarbonyl. Further examples of groups referred to by the above
terms are described by E. Haslam, PROTECTIVE GROUPS IN ORGANIC
CHEMISTRY, (J.G.W. McOmie, ed., 1973), at Chapter 2; and T.W. Greene
25 and P.G.M. Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (1991), at
Chapter 7.


The term "leaving group" as used herein refers to a group of
atoms that is displaced from a carbon atom by the attack of a nucleophile
in a nucleophilic substitution reaction. The term "leaving group" as used
30 in this document encompasses, but is not limited to, activating groups.

The term "activating group" as used herein refers a leaving
group which, when taken with the carbonyl (-C=O) group to which it is
attached, is more likely to take part in an acylation reaction than would
be the case if the group were not present, as in the free acid. Such
35 activating groups are well-known to those skilled in the art and may be,

- 10 -

for example, succinimidoxy, phthalimidoxy, benzotriazolyloxy, benzenesulfonyloxy, methanesulfonyloxy, toluenesulfonyloxy, azido, or -O-CO-(C₄-C₇ alkyl).

5 The term "haloformate" as used herein refers to an ester of a haloformic acid, this compound having the formula



10 wherein X is halo, and R^e is C₁-C₆ alkyl. Preferred haloformates are bromoformates and chloroformates. Especially preferred are chloroformates. Those haloformates wherein R³ is C₃-C₆ alkyl are preferred. Most preferred is isobutyl chloroformate.

15 The compounds used in the method of the present invention may have one or more asymmetric centers. As a consequence of these chiral centers, the compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All asymmetric forms, individual isomers and combinations thereof, are within the scope of the present invention.

20 The terms "R" and "S" are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term "R" (*rectus*) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term "S" 25 (*sinister*) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in NOMENCLATURE OF ORGANIC 30 COMPOUNDS: PRINCIPLES AND PRACTICE, (J.H. Fletcher, et al., eds., 1974) at pages 103-120.

In addition to the (R)-(S) system, the older D-L system is also used in this document to denote absolute configuration, especially with

- 11 -

reference to amino acids. In this system a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top. The prefix "D" is used to represent the absolute configuration of the isomer in which the functional (determining) group is on the right side of the carbon atom at the chiral center and "L", that of the isomer in which it is on the left.

In order to preferentially prepare one optical isomer over its enantiomer, the skilled practitioner can proceed by one of two routes. The practitioner may first prepare the mixture of enantiomers and then separate the two enantiomers. A commonly employed method for the resolution of the racemic mixture (or mixture of enantiomers) into the individual enantiomers is to first convert the enantiomers to diastereomers by way of forming a salt with an optically active acid or base. These diastereomers can then be separated using differential solubility, fractional crystallization, chromatography, or like methods. Further details regarding resolution of enantiomeric mixtures can be found in J. Jacques, et al., ENANTIOMERS, RACEMATES, AND RESOLUTIONS, (1991).

In addition to the schemes described above, the practitioner of this invention may also choose an enantiospecific protocol for the preparation of the compounds of Formula I. Such a protocol employs a synthetic reaction design which maintains the chiral center present in the starting material in a desired orientation. These reaction schemes usually produce compounds in which greater than 95 percent of the title product is the desired enantiomer.

As noted supra, this invention includes the pharmaceutically acceptable salts of the compounds defined by Formula I. Although generally neutral, a compound of this invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

The term "pharmaceutically acceptable salt" as used herein, refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds

- 12 -

of the present invention with a pharmaceutically acceptable mineral or organic acid or an inorganic base. Such salts are known as acid addition and base addition salts.

Acids commonly employed to form acid addition salts are
5 inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as *p*-toluenesulfonic, methanesulfonic acid, oxalic acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically
10 acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate,
15 fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-
20 sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.

Salts of amine groups may also comprise quaternary
25 ammonium salts in which the amino nitrogen carries a suitable organic group such as an alkyl, alkenyl, alkynyl, or aralkyl moiety.

Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the
30 salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred.

- 13 -

It should be recognized that the particular counterion forming a part of any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.

This invention further encompasses the pharmaceutically acceptable solvates of the compounds of Formula I. Many of the Formula I compounds can combine with solvents such as water, methanol, ethanol and acetonitrile to form pharmaceutically acceptable solvates such as the corresponding hydrate, methanolate, ethanolate and acetonitrilate.

This invention also encompasses the pharmaceutically acceptable prodrugs of the compounds of Formula I. A prodrug is a drug which has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other *in vivo* processes to the parent bioactive form. This prodrug should have a different pharmacokinetic profile than the parent, enabling easier absorption across the mucosal epithelium, better salt formation or solubility, or improved systemic stability (an increase in plasma half-life, for example).

Typically, such chemical modifications include:

1) ester or amide derivatives which may be cleaved by esterases or lipases;

2) peptides which may be recognized by specific or nonspecific proteases; or

3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or a modified prodrug form; or any combination of 1 to 3, *supra*. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in H, Bundgaard, DESIGN OF PRODRUGS, (1985).

The preferred methods of the present invention employ the preferred compounds of the present invention. The preferred compounds of the present invention are those compounds of Formula I in which:

(1) at least one of R¹, R², and R³ is not hydrogen;

35

- 14 -

- (2) A is methylene or ethylene;
- (3) R^a and R^b are both hydrogen, or R^a and R^b combine to form a bond; and
- 5 (4) at least one of R⁴ and R⁵ is chloro, fluoro, hydroxy, trifluoromethyl, methoxy, ethoxy, methyl, benzamido, and phenyl(C₂-C₇ carbamoyl)-, or a substituted derivative thereof.


10

Especially preferred are those compounds of Formula I in which:


- (1) A is methylene;
- 15 (2) R¹, R², and R³, together with the phenyl group to which they are bound, form, 2-methoxyphenyl, 2-chlorophenyl, 2-methylphenyl, 2-trifluoromethylphenyl, 3,4-dimethoxyphenyl, 3,4-dichlorophenyl, 3,4-bis(trifluoromethyl)phenyl, 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4,5-trimethylphenyl, 3,4,5-tri(trifluoromethyl)phenyl, 3,5-dimethoxyphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, or 3,5-bis(trifluoromethyl)phenyl;
- 20 (3) R^a and R^b are both hydrogen, or R^a and R^b combine to form a bond; and
- 25 (4) at least one of R⁴ and R⁵ is chloro, fluoro, hydroxy, trifluoromethyl, methoxy, ethoxy, methyl, benzamido, and phenyl(C₂-C₇ carbamoyl)-, or a substituted derivative thereof, substituted at the five and/or six position of the indolyl moiety.
- 30

35 The compounds of the present invention may be prepared by reacting a compound of Formula II

- 15 -



where X is a leaving group, preferably a halo group, most preferably
 5 bromo or iodo, with a compound of Formula III.



10 This reaction is generally performed in an organic solvent, at
 a temperature between -78°C and 120°C , and the resulting product is
 isolated. This reaction is generally performed using equimolar amounts of
 the two reactants, even though other ratios may also be employed. The
 organic solvent used is preferably a polar aprotic solvent, for example,
 15 acetonitrile, N,N-dimethylformamide, N,N-dimethylphenylacetamide,
 dimethylsulfoxide, or hexamethylphosphoric triamide. Instead of using a
 polar aprotic solvent it is also possible to use an ether, such as
 tetrahydrofuran, dioxane, or methyl *t*-butyl ether, or a ketone, such as
 methyl ethyl ketone. Acetonitrile is the most preferred such solvent.


20 In the temperature range indicated above, the preferred
 temperature is $30-90^{\circ}\text{C}$. If acetonitrile is employed as a solvent, the

- 16 -


reaction is advantageously carried out at the reflux point of the reaction mixture.

The product obtained in this way is isolated by the usual techniques, for example, by concentration of the solvents, followed by washing of the residue with water, and then purification by conventional techniques, such as chromatography or recrystallization.

The compounds of the present invention may also be prepared by reacting a compound of Formula IV



with a compound of Formula V




where X is a leaving group, preferably a halo group, most preferably bromo or iodo. The reaction conditions and the solvent employed for this reaction are essentially the same as for the reaction of the compounds of Formula II and III, *supra*.


- 17 -

The most preferred method of synthesizing the intermediates of Formulae II and IV is depicted in Scheme I, infra. Many of the steps of this synthesis are described in Patent Cooperation Treaty Publication WO 95/14017, published May 26, 1995, and European Patent Application
5 Publication 693,489, to be published January 24, 1996.

- 18 -

Scheme I

wherein "Tr" refers to a trityl group, and "NMM" refers to N-methylmorpholine.

Scheme I (continued)

- 20 -

The coupling of the protected amine to the substituted benzylamine, as depicted in step (b), can be performed by many means known in the art, the particular methods employed being dependent upon the particular benzylamine which is used as the starting material and the type of protected amine used in the coupling reaction. These coupling reactions frequently employ commonly used coupling reagents such as 1,1-carbonyl diimidazole, dicyclohexylcarbodiimide, diethyl azodicarboxylate, 1-hydroxybenzotriazole, alkyl chloroformate and triethylamine, phenyldichlorophosphate, and chlorosulfonyl isocyanate. Examples of these methods are described infra.

In the above process, in step (c), the intermediate amides are reduced to amines using procedures well known in the art. These reductions can be performed using lithium aluminum hydride as well as by use of many other different aluminum-based hydrides. An especially preferred reagent employed in this reduction is RED-AL[®], which is the tradename of a 3.4 M solution of sodium bis(2-methoxyethoxy)aluminum hydride in toluene. Alternatively, the amides can be reduced by catalytic hydrogenation, though high temperatures and pressures are usually required for this. Sodium borohydride in combination with other reagents may be used to reduce the amide. Borane complexes, such as a borane dimethylsulfide complex, are especially useful in this reduction reaction.

The acylation of the secondary amine can be done using any of a large number of techniques regularly employed by those skilled in organic chemistry. One such reaction scheme is a substitution using an anhydride such as acetic anhydride. Another reaction scheme often employed to acylate a secondary amine employs a carboxylic acid preferably with an activating agent. An amino-de-alkoxylation type of reaction uses esters as a means of acylating the amine. Activated esters which are attenuated to provide enhanced selectivity are very efficient acylating agents. One preferred such activated ester is *p*-nitrophenyl ester, such as *p*-nitrophenyl acetate.

The amine is then deprotected using standard techniques. The particular deprotecting agents and conditions employed will depend upon the amino-protecting group utilized. For those compounds in which a trityl group is used to protect the amine, the use of dry gaseous

- 21 -


hydrogen chloride in a suitable solvent, such as dry ethyl ether, is especially preferred.

The following Preparations and Examples further illustrate the compounds of the present invention and the methods for their synthesis. The Preparations and Examples are not intended to be limiting to the scope of the invention in any respect, and should not be so construed. All solvents and reagents were purchased from commercial sources and used as received, unless otherwise indicated. Dry tetrahydrofuran (THF) was obtained by distillation from sodium or sodium benzophenone ketyl prior to use.

The starting materials described herein are commercially available or may be prepared by methods well known to those in the art.

Preparation A

Preparation of (R)-3-(1H-indol-3-yl)-2-(N-triphenylmethylamino)propanoic acid, N-methylmorpholine salt (N-trityl-D-tryptophan N-methylmorpholine salt).



To a one liter 4 neck flask equipped with mechanical stirrer, condensor, probe, and stopper, were added D-tryptophan (40.0 g, 0.196 mol), acetonitrile (240 ml), and 1,1,1,3,3,3-hexamethyldisilazane (39.5 g, 0.245 mol). The resulting mixture was heated to 50-60°C and stirred until homogeneous. In a separate beaker trityl chloride (60.06 g, 0.215 mol) and acetonitrile (120 ml) were slurried. The slurry was added to the silylated tryptophan mixture and the beaker was rinsed with 40 ml of acetonitrile. To the reaction mixture N-methylmorpholine (23.7 ml, 21.8 g, 0.216 mol) was added and the resulting mixture was stirred for one hour. The progress of the reaction was monitored by chromatography.

After satisfactory progress, water (240 ml) was added dropwise to the reaction mixture and the resulting mixture was cooled to

- 22 -

less than 10°C, stirred for thirty minutes, and filtered. The residue was washed with water, and then dried to obtain 108.15 grams (>99% yield) of the desired title product.

¹H NMR (DMSO-d₆) δ 2.70 (m, 1H), 2.83 (m, 2H), 3.35 (m, 1H), 6.92-7.20 (m, 12H), 7.30-7.41 (m, 8H), 10.83 (s, 1H), 11.73 (br s, 1H).

Analysis for C₃₀H₂₆N₂O₂:


Theory: C, 80.69; H, 5.87; N, 6.27.

Found: C, 80.47; H, 5.92; N, 6.10.

Those intermediates of Formulae II and IV in which the stereochemistry is in the (S) configuration may be prepared essentially as described above, except that L-tryptophan is employed in place of the D-tryptophan employed therein. The resulting enantiomer may then be utilized as described below.

Preparation B

Preparation of (R)-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)-2-(N-triphenylmethylamino)propanamide.



To a two liter 4 neck flask equipped with mechanical stirrer, condensor, and thermocouple, under a nitrogen atmosphere, were added N-trityl-D-tryptophan N-methylmorpholine salt (108.0 g, 0.196 mol), acetonitrile (800 ml), 2-chloro-4,6-dimethoxy-1,3,5-triazine (38.63 g, 0.22 mol), and N-methylmorpholine (29.1 ml). The resulting mixture was stirred at ambient temperature until homogeneous (about ten minutes).

After about one hour, 2-methoxybenzylamine (29 ml) was added. The resulting mixture was heated to 35°C and maintained at that temperature overnight. The progress of the reaction was monitored by chromatography. Water (750 ml) was then added dropwise to the reaction

- 23 -

mixture and the resulting mixture was cooled to less than 10°C, stirred for thirty minutes, and filtered. The residue was washed with water (about 100 ml), and then dried to obtain the desired title product. (Yield: 87% and 91% in two runs)

5 FDMS 565 (M⁺).

¹H NMR (CDCl₃) δ 2.19 (dd, J=6.4 Hz, Δν=14.4 Hz, 1H), 2.64 (d, J=6.5 Hz, 1H), 3.19 (dd, J=4.3 Hz, Δν=14.4 Hz, 1H), 3.49 (m, 1H), 3.63 (s, 3H), 3.99 (dd, J=5.4 Hz, Δν=14.2 Hz, 1H), 4.25 (dd, J=7.1 Hz, Δν=14.2 Hz, 1H), 6.64 (d, J=2.1 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.91 (t, J=7.4 Hz, 1H), 7.06-7.38

10 (m, 21 H), 7.49 (d, J=7.9 Hz, 1H), 7.75 (s, 1H).

Analysis for C₃₈H₃₅N₃O₂:


Theory: C, 80.68; H, 6.24; N, 7.43.

Found: C, 80.65; H, 6.46; N, 7.50.

15

Preparation C

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(2-chlorobenzyl)propanamide



20

The title compound is prepared essentially as described above in Preparation B except that 2-chlorobenzylamine is employed instead of 2-methoxybenzylamine.


25

- 24 -

Preparation D

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(2-methylbenzyl)propanamide

5




The title compound is prepared essentially as described above in Preparation B except that 2-methylbenzylamine is employed instead of 2-methoxybenzylamine.

10

Preparation E

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(2-methylthiobenzyl)propanamide

15



The title compound is prepared essentially as described above in Preparation B except that 2-methylthiobenzylamine is employed instead of 2-methoxybenzylamine.


20

Preparation F

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(2-trifluoromethylbenzyl)propanamide

25


- 25 -



The title compound is prepared essentially as described above in Preparation B except that 2-trifluoromethylbenzylamine is employed instead of 2-methoxybenzylamine.

Preparation G


Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(4-chlorobenzyl)propanamide



The title compound is prepared essentially as described above in Preparation B except that 4-chlorobenzylamine is employed instead of 2-methoxybenzylamine.

Preparation H

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(4-methylbenzyl)propanamide




- 26 -

The title compound is prepared essentially as described above in Preparation B except that 4-methylbenzylamine is employed instead of 2-methoxybenzylamine.

5

Preparation I

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(4-methoxybenzyl)propanamide




10

The title compound is prepared essentially as described above in Preparation B except that 4-methoxybenzylamine is employed instead of 2-methoxybenzylamine.

15

Preparation J

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(4-trifluoromethylbenzyl)propanamide



20


The title compound is prepared essentially as described above in Preparation B except that 4-trifluoromethylbenzylamine is employed instead of 2-methoxybenzylamine.

25

Preparation K

- 27 -

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(3,4-dichlorobenzyl)propanamide




5

The title compound is prepared essentially as described above in Preparation B except that 3,4-dichlorobenzylamine is employed instead of 2-methoxybenzylamine.

10

Preparation L

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(3,4-dimethylbenzyl)propanamide



15


The title compound is prepared essentially as described above in Preparation B except that 3,4-dimethylbenzylamine is employed instead of 2-methoxybenzylamine.

20

Preparation M

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-(3,4-dimethoxybenzyl)propanamide

25



- 28 -


The title compound is prepared essentially as described above in Preparation B except that 3,4-dimethoxybenzylamine is employed instead of 2-methoxybenzylamine.

5

Preparation N

Preparation of (R)-2-amino-3-(1H-indol-3-yl)-N-[3,4-bis(trifluoromethyl)benzyl]propanamide

10




The title compound is prepared essentially as described above in Preparation B except that 3,4-bis(trifluoromethyl)benzylamine is employed instead of 2-methoxybenzylamine.

15

Preparation O

Reduction of Carbonyl

20



Preparation of (R)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)amino]-2-(N-triphenylmethylamino)propane

25

RED-AL[®]. [a 3.4 M, solution of sodium bis(2-methoxyethoxy)aluminum hydride in toluene] (535 ml, 1.819 mol), dissolved in anhydrous tetrahydrofuran (400 ml) was slowly added using an addition funnel to a refluxing solution of the acylation product, (R)-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)-2-(N-

30


- 29 -

triphenylmethylamino)propanamide (228.6 g, 0.404 mol) produced supra,
 in anhydrous tetrahydrofuran (1.0 L) under a nitrogen atmosphere. The
 reaction mixture became a purple solution. The reaction was quenched
 after at least 20 hours by the slow addition of excess saturated Rochelle's
 5 salt solution (potassium sodium tartrate tetrahydrate). The organic layer
 was isolated, washed with brine (2X), dried over anhydrous sodium
 sulfate, filtered, and concentrated to an oil on a rotary evaporator. No
 further purification was done and the product was used directly in the
 next step.

10

Preparation P

Acylation of Secondary Amine



15

Preparation of (R)-3-(1H-indol-3-yl)-2-(tritylamino)-N-[(2-
 methoxybenzyl)acetyl]-N-acetylpropanamine

20

To a stirring solution of (R)-3-(1H-indol-3-yl)-1-[N-(2-
 methoxybenzyl)amino]-2-(N-triphenylmethylamino)propane (0.404 mol) in
 anhydrous tetrahydrofuran (1.2 L) under a nitrogen atmosphere at 0°C
 was added triethylamine (66.5 ml, 0.477 mol) and acetic anhydride (45.0
 ml, 0.477 mol). After 4 hours, the mixture was concentrated on a rotary
 25 evaporator, redissolved in methylene chloride and ethyl acetate, washed
 with water (2X) and brine (2X), dried over anhydrous sodium sulfate,
 filtered, and concentrated to a solid on a rotary evaporator. The resulting
 solid was dissolved in chloroform and loaded onto silica gel 60 (230-400
 mesh) and eluted with a 1:1 mixture of ethyl acetate and hexanes. The
 30 product was then crystallized from an ethyl acetate/hexanes mixture. The
 resulting product of (R)-3-(1H-indol-3-yl)-1-[N-(2-
 methoxybenzyl)acetyl]amino]-2-(N-triphenylmethylamino)propane was

- 30 -

crystallized and isolated over three crops giving 208.97 grams (87% yield) of analytically pure material.

Analysis for $C_{40}H_{39}N_3O_2$:


Theory: C, 80.91; H, 6.62; N, 7.08.

5 Found: C, 81.00; H, 6.69; N, 6.94.

Preparation Q

Deprotection

10



Preparation of (R)-3-(1H-indol-3-yl)-2-amino-N-[(2-methoxybenzyl)acetyl]-N-acetylpropanamine dihydrochloride

15

A stirring solution of (R)-3-(1H-indol-3-yl)-2-(tritylamino)-N-[(2-methoxybenzyl)acetyl]-N-acetylpropanamine in two volumes of methylene chloride was cooled to between -40°C and -50°C . Anhydrous hydrogen chloride gas was added at such a rate that the temperature of the reaction mixture did not exceed 0°C . The reaction mixture was stirred for 30 minutes to one hour at $0-10^{\circ}\text{C}$.

20

To this reaction mixture was added two volumes of methyl *t*-butyl ether and the resulting mixture was allowed to stir for 30 minutes to one hour at $0-10^{\circ}\text{C}$. The resulting crystalline solid was removed by filtration and then washed with methyl *t*-butyl ether. The reaction product was dried under vacuum at 50°C . (Yield >98%)

25

Analysis for $C_{21}H_{25}N_3O_2 \cdot 2 \text{HCl}$:

Theory: C, 59.44; H, 6.41; N, 9.90.

Found: C, 60.40; H, 6.60; N, 9.99.


30

Preparation R

Bromoacetylation

Preparation of 2-[(2-bromo)acetyl]amino-3-(1H-indol-3-yl)-1-[N-acetyl-N-(2-methoxybenzyl)amino]propane

5



To a stirring solution of 2-amino-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetyl]amino]propane (7.51 g, 21.369 mmoles) in
10 anhydrous tetrahydrofuran (100 ml) under a nitrogen atmosphere at 0°C
was added diisopropylethylamine (4.1 ml, 23.537 mmoles) and
bromoacetyl bromide (2.05 ml, 23.530 mmoles). After 2 hours, ethyl
acetate was added and the reaction mixture washed with water twice, 1.0
N hydrochloric acid (2X), saturated sodium bicarbonate solution (2X), and
15 brine. The organic layer was dried over anhydrous sodium sulfate,
filtered, and concentrated to a tan foam on a rotary evaporator. In this
manner the 2-[(2-bromo)acetyl]amino-3-(1H-indol-3-yl)-1-[N-(2-
methoxybenzyl)acetyl]amino]propane was obtained in quantitative yield.
No further purification was necessary.

20


The other compounds of Formulae II and IV may be prepared
as described in Preparations O-R, *supra*, employing the propanamides of
Preparations C-N.

25

The compounds of Formulae III and V may be prepared by
methods well known to one of ordinary skill in the art. A majority of the
starting indoles are commercially available, however, they may be
prepared by the Fischer indole synthesis (Robinson, THE FISCHER INDOLE
SYNTHESIS, Wiley, New York, 1983).

- 32 -

The indoles are condensed with 4-piperidone · HCl · H₂O in the presence of a suitable base to give the corresponding 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indoles as illustrated in the following scheme.



5


The reaction is performed by first dissolving an excess of the base, typically sodium or potassium hydroxide, in a lower alkanol, typically methanol or ethanol. The indole and two equivalents of 4-piperidone · HCl · H₂O are then added and the reaction refluxed for 8-72 hours. The resulting 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indoles may be isolated from the reaction mixture by the addition of water. Compounds which precipitate may be isolated directly by filtration while others may be extracted with a water immiscible solvent such as ethyl acetate or dichloromethane. The compounds recovered may be used directly in subsequent steps or first purified by silica gel chromatography or recrystallization from a suitable solvent.

10

15

20

The 3-(1,2,5,6-tetrahydro-4-pyridinyl)-1H-indoles may next be hydrogenated to give the corresponding 3-(piperidin-4-yl)-1H-indoles as shown below.



25

The catalyst may be a precious metal catalyst such as platinum oxide, or palladium or platinum on a suitable support such as carbon. When X is a


- 33 -

functional group that is labile to hydrogenolysis, such as halo or benzyloxy, a deactivated catalyst such as sulfided platinum on carbon or a mixed catalyst system of sulfided platinum on carbon with platinum oxide may be used to prevent hydrogenolysis. The solvent may consist of a lower alkanol, such as methanol or ethanol, tetrahydrofuran or a mixed solvent system of tetrahydrofuran and ethyl acetate. The hydrogenation may be performed at an initial hydrogen pressure of 20-80 p.s.i., preferably from 50-60 p.s.i., at 0-60°C, preferably at ambient temperature to 40°C, for 1 hour to 3 days. Additional charges of hydrogen may be required to drive the reaction to completion depending on the specific substrate. The 3-(piperidin-4-yl)-1H-indoles prepared in this manner are isolated by removal of the catalyst by filtration followed by concentration of the reaction solvent under reduced pressure. The product recovered may be used directly in a subsequent step or further purified by chromatography or recrystallization from a suitable solvent.

All of the 3-[1,2,3,6-tetrahydro-4-pyridinyl]-1H-indoles useful as intermediates for compounds of this invention may be prepared as described in the following procedure.

Preparation 1

5-bromo-3-[1,2,3,6-tetrahydro-4-pyridinyl]-1H-indole



To a solution of 4.29 gm (77 mmol) potassium hydroxide in 50 ml methanol were added 5.0 gm (26 mmol) 5-bromoindole and 7.84 gm (51 mmol) 4-piperidone · HCl · H₂O and the reaction mixture was stirred for 18

- 34 -


hours at reflux under a nitrogen atmosphere. The reaction mixture was cooled to ambient temperature, diluted with 500 ml water and the mixture extracted well with dichloromethane. The combined organic extracts were washed with water followed by saturated aqueous sodium chloride and dried over sodium sulfate. The remaining organics were concentrated under reduced pressure to give 6.23 gm (86.5%) of the title compound as a yellow oil.

$^1\text{H-NMR(DMSO-d}_6\text{)}$: δ 8.00 (s, 1H); 7.40 (s, 1H); 7.30(d, 1H); 7.20 (d, 1H); 6.10 (s, 1H); 3.35 (br s, 2H); 2.85 (m, 2H); 2.35 (br s, 2H).

All of the 3-[piperidin-4-yl]-1H-indoles useful as intermediates for compounds of this invention may be prepared as described in the following procedure.

Preparation 2

5-bromo-3-[piperidin-4-yl]-1H-indole



To a solution of 13.61 gm (49 mmol) 5-bromo-3-[1,2,3,6-tetrahydro-4-pyridinyl]-1H-indole in 75 ml 2:1 tetrahydro-furan:ethyl acetate were added 8.0 gm 3% sulfided platinum on carbon and 4.0 gm platinum oxide. The reaction mixture was hydrogenated with an initial hydrogen pressure of 60 p.s.i. at 40°C for 18 hours and then at ambient temperature for 30 hours. The reaction mixture was filtered and the filtrate concentrated under reduced pressure to give 10.33 gm (75.6%) of the title compound as a light yellow solid.

MS(m/e): 278(M⁺).


- 35 -

$^1\text{H-NMR(DMSO-d}_6\text{)}$: δ 10.6 (s, 1H); 7.2 (d, 1H); 7.05 (s, 2H); 6.7 (d, 1H); 3.15 (s, 1H); 3.05 (s, 1H); 2.8 (m, 3H), 1.95 (s, 1H); 1.85 (s, 1H); 1.6 (m, 2H).

5

Preparation 3

5-carboxamidoindole



10

To a solution of 8.06 gm (50 mmol) indole-5-carboxylic acid in 150 ml dimethylformamide were added 8.11 gm (50 mmol) carbonyldiimidazole and the reaction mixture stirred at ambient temperature for 3 hours. The reaction mixture was then added dropwise to 150 ml concentrated ammonium hydroxide and the reaction mixture was stirred for 18 hours at ambient temperature. The reaction mixture was concentrated under reduced pressure to give a viscous oil which was subjected to silica gel chromatography, eluting with a gradient of dichloromethane containing 0-10% methanol. Fractions shown to contain product were combined and concentrated under reduced pressure to give the title compound as an oil which crystallizes upon standing.

$^1\text{H-NMR(CDCl}_3\text{)}$: δ 8.18 (s, 1H); 7.74 (d, 1H); 7.45 (d, 1H); 7.35 (s, 1H); 6.65 (s, 1H).

15

20

25


The other compounds of Formula III may be prepared essentially as described above using commercially available starting materials. The compounds of Formula V may be prepared from the corresponding compound of Formula III essentially as described in Preparation R.

30

Example 1

- 36 -

Preparation of (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine



5

A 10 ml tear drop flask was charged with 2-[(2-bromo)acetyl]amino-3-(1H-indol-3-yl)-1-[N-acetyl-[N-(2-methoxybenzyl)acetyl]amino]propane (0.10 g, 0.2 mmol), powdered potassium carbonate (0.117 g, 0.84 mmol) and 4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridine (0.078 g, 0.212 mmol). To the resulting mixture was added 2.0 ml of N,N-dimethylformamide. The resulting mixture was then placed under a nitrogen atmosphere and permitted to stir overnight. The progress of the reaction was monitored by thin layer chromatography.

The reaction mixture was then poured into water and the solids were collected by vacuum filtration. The solids were dried in a vacuum oven overnight to yield 0.1458 grams (97% yield) of the desired title product.

MS: Theory: 723.3659 Found: 723.3688

20

- 37 -

Analysis for $C_{44}H_{46}N_6O_4$:


Theory: C, 73.11; H, 6.41; N, 11.63.

Found: C, 70.76; H, 6.40; N, 11.40.

5

Example 2

Preparation of (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine



10

A 10 ml round bottom flask was charged with 2-[(2-bromo)acetyl]amino-3-(1H-indol-3-yl)-1-[N-acetyl-[N-(2-methoxybenzyl)acetyl]amino]propane (0.10 g, 0.212 mmol), powdered potassium carbonate (0.117 g, 0.84 mmol) and 4-[5-(hydroxy)indol-3-yl]piperidine (0.055 g, 0.212 mmol). To the resulting mixture was added 2.0 ml of N,N-dimethylformamide. The resulting mixture was then placed under a nitrogen atmosphere and permitted to stir overnight. The progress of the reaction was monitored by thin layer chromatography.

The reaction mixture was then poured into ice water and the solids were collected by vacuum filtration. The solids were dried in a vacuum oven overnight to yield 0.1092 grams (99%) of the desired title product, which was further purified by thin layer chromatography.

Analysis for $C_{36}H_{41}N_5O_4$:

- 38 -


Theory: C, 71.15; H, 6.80; N, 11.52.

Found: C, 71.07; H, 6.95; N, 11.42.

5 The following compounds were prepared essentially as described supra.

Example 3

10 Preparation of (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine




15

Example 4


Preparation of (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine

20

- 39 -

Example 5

- 5 Preparation of (R)-2-[[4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido]-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine




10

Example 6

- 40 -

Preparation of (R)-2-[[4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido]-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine



5

Analysis for $C_{36}H_{40}ClN_5O_3$:

Theory: C, 69.05; H, 6.44; N, 11.18.

Found: C, 66.77; H, 6.40; N, 10.83.


10

Example 7

Preparation of (R)-2-[[4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido]-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine

15

- 41 -



Analysis for $C_{43}H_{45}FN_6O_4$:


Theory: C, 70.86; H, 6.22; N, 11.53.

5 Found: C, 70.34; H, 6.78; N, 10.47.

Example 8


10 Preparation of (R)-2-([4-[5-(1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]acetamido]-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine

- 42 -



Example 9

- 5 Preparation of (R)-2-[[4-[5-(chloro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido]-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine



- 43 -

Analysis for C₃₆H₃₈ClN₅O₃:

Theory: C, 69.27; H, 6.14; N, 11.22.

Found: C, 67.51; H, 5.97; N, 10.90.

5 Using procedures analogous to those of Examples 1 through 9
and the intermediates described in the Preparations *infra*, the following
other compounds of Formula I are prepared: (R)-2-{{4-[5-(4-
fluorobenzamido)indol-3-yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-
acetyl-N-(2-methoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-
10 yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-
tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-
15 tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-
yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-
yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-
20 yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-
N-(2-methoxybenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-
tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-
25 yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
chlorobenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-
yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-chlorobenzyl)propanamine;
(R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-
(1H-indol-3-yl)-N-acetyl-N-(2-chlorobenzyl)propanamine; (R)-2-{{4-[5-
30 (methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-
indol-3-yl)-N-acetyl-N-(2-chlorobenzyl)propanamine; (R)-2-{{4-[5-
(hydroxy)indol-3-yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-
N-(2-chlorobenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-
yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-chlorobenzyl)propanamine;
(R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-
35 1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-

- 44 -

chlorobenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-chlorobenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methylbenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-trifluoromethylbenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-

3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4-dichlorobenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-

- 46 -

trimethylbenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,4,5-trimethylbenzyl)propanamine; (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine; and (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(3,5-dimethoxybenzyl)propanamine. It should be readily apparent to one skilled in the art that a large number of other compounds of Formula I may be prepared using other intermediates prepared essentially as described *infra*. Such other compounds of Formula I are within the scope of this invention.

- 47 -

The biological efficacy of a compound believed to be effective as a serotonin agonist may be confirmed by first employing an initial screening assay which rapidly and accurately measures the binding of the test compound to one or more serotonin receptors. Once the binding of the test compound to one or more serotonin receptors is established, the in vivo activity of the test compound on the receptor is established. Assays useful for evaluating serotonin agonists are well known in the art. See, e.g., E. Zifa and G. Fillion, infra; D. Hoyer, et al., infra, and the references cited therein.

Many serotonin binding receptors have been identified. These receptors are generally grouped into seven classes on the basis of their structure and the pharmacology of the receptor as determined by the binding efficiency and drug-related characteristics of numerous serotonin receptor-binding compounds. In some of the groups several subtypes have been identified. [For a relatively recent review of 5-hydroxytryptamine receptors, see, E. Zifa and G. Fillion, Pharmacological Reviews, 44:401-458 (1992); D. Hoyer, et al., Pharmacological Reviews, 46:157-203 (1994).] Table I, infra, lists the seven classes of serotonin receptors as well as several known subtypes. This table also provides the physiological distribution of these receptors as well as biological responses mediated by the receptor class or subtype, if any such response is known. This table is derived from D. Hoyer, et al., "VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)", Pharmacological Reviews, 46:157-203 (1994), a publication of the Serotonin Club Receptor Nomenclature Committee of the IUPHAR Committee for Receptor Nomenclature.

The Hoyer, et al., reference describes for each class or subtype one or more compounds which have efficacy as antagonists or agonists for the receptor.

The 5-HT₁ family includes subtypes which can be grouped together based on the absence of introns in the cloned genes, a common G-coupled protein transduction system (inhibition of adenylate cyclase), and similar operational characteristics. The 5-HT₁ family of inhibitory receptors includes subtypes A, B, D, E, and F. The 5-HT₁ G protein-linked receptors general inhibit the production of cyclic adenosine

- 48 -

monophosphate (cAMP), while the 5-HT₂ G protein linked receptors stimulate phosphoinositol hydrolysis.

The 5-HT_{1A} receptor was the first cloned human serotonin receptor. Activated 5-HT_{1A} receptors expressed in HeLa cells inhibit
5 forskolin-stimulated adenylate cyclase activity. The 5-HT_{1D} receptor was originally identified in bovine brain membrane by Heuring and Peroutka. R.E. Heuring and S.J. Peroutka, Journal of Neuroscience, 7:894-903 (1987). The 5-HT_{1D} receptors are the most common 5-HT receptor subtype in the human brain and may be identical to the 5-HT₁-like
10 receptor in the cranial vasculature. S.D. Silberstein, Headache, 34:408-417 (1994). Sumatriptan and the ergot alkaloids have high affinity for both the human 5-HT_{1D} and the 5-HT_{1B} receptors. Id.

The 5-HT_{1F} subtype of receptor has low affinity for 5-carboxamidotryptamine (5-CT) unlike the other 5-HT receptors, except for
15 the 5-HT_{1E} subtype. Unlike the 5-HT_{1E} receptors, however, the 5-HT_{1F} receptors do show affinity for sumatriptan.

- 49 -

Table I

Receptor Type	Subtype	Location	Response
5-HT ₁	5-HT _{1A}	Neuronal, mainly in CNS	Neuronal hyperpolarisation, hypotension
	5-HT _{1B}	CNS and some peripheral nerves	Inhibition of neurotransmitter release
	5-HT _{1D}	Mainly CNS	Inhibition of neurotransmitter release
	5-HT _{1E}	Only CNS	Inhibition of adenylyl cyclase
	5-HT _{1F}	Mainly CNS	Inhibition of adenylyl cyclase
	5-HT _{1-like}	Intracranial vasculature	Smooth muscle contraction
5-HT ₂	5-HT _{2A}	Vascular smooth muscle, platelets, lung, CNS, gastrointestinal tract	Vasoconstriction, platelet aggregation, bronchoconstriction
	5-HT _{2B}	Mainly peripheral, some CNS	Rat stomach fundic muscle contraction
	5-HT _{2C}	CNS (high density in choroid plexus)	upregulates phosphoinositide turnover
5-HT ₃		Peripheral and central neurones	Depolarization
5-HT ₄		Gastrointestinal tract, CNS, heart, urinary bladder	Activation of acetylcholine release in gut, tachycardia, upregulates cAMP in CNS neurones
5-HT ₅	5-HT _{5A}	CNS	Not known
	5-HT _{5B}	CNS	Not known
5-HT ₆		CNS	Activation of adenylyl cyclase
5-HT ₇		CNS	Activation of adenylyl cyclase

Serotonin Receptor Binding Activity

Binding to the 5-HT_{1F} receptor.

5 The ability of a compound to bind to a serotonin receptor was measured using standard procedures. For example, the ability of a compound to bind to the 5-HT_{1F} receptor subtype was performed essentially as described in N. Adham, et al., Proceedings of the National Academy of Sciences (USA), 90:408-412 (1993).

10 The cloned 5-HT_{1F} receptor was expressed in stably transfected LM(tk⁻) cells. Membrane preparations were made by growing these transfected cell lines to confluency. The cells were washed twice with phosphate-buffered saline, scraped into 5 ml of ice-cold phosphate-buffered saline, and centrifuged at 200 x g for about five minutes at 4°C.

15 The pellet was resuspended in 2.5 ml of cold Tris buffer (20 mM Tris-HCl, pH 7.4 at 23°C, 5 mM EDTA) and homogenized. The lysate was centrifuged at 200 x g for about five minutes at 4°C to pellet large fragments. The supernatant was then centrifuged at 40,000 x g for about 20 minutes at 4°C. The membranes were washed once in the

20 homogenization buffer and resuspended in 25 mM glycylglycine buffer, pH 7.6 at 23°C.

 Radioligand binding studies were performed using [³H]5-HT (20-30 Ci/mmol). Competition experiments were done by using various concentrations of drug and 4.5-5.5 nM [³H]5-HT. Nonspecific binding was

25 defined by 10 μM 5-HT. Binding data were analyzed by nonlinear-regression analysis. IC₅₀ values were converted to K_i values using the Cheng-Prusoff equation.

 For comparison purposes, the binding affinities of compounds

30 for various serotonin receptors may be determined essentially as described above except that different cloned receptors are employed in place of the 5-HT_{1F} receptor clone employed therein.

Serotonin Agonist Activity

35

- 51 -

Adenylate Cyclase Activity.

Adenylate cyclase activity was determined in initial experiments in LM(tk-) cells, using standard techniques. See, e.g., N. Adham, et al., supra.; R.L. Weinshank, et al., Proceedings of the National Academy of Sciences (USA), 89:3630-3634 (1992), and the references cited therein.

Intracellular levels of cAMP were measured using the clonally derived cell line described above. Cells were preincubated for about 20 minutes at 37°C in 5% carbon dioxide, in Dulbecco's modified Eagle's medium containing 10 mM HEPES, 5 mM theophylline, and 10 μM pargyline. Varying concentrations of the test compounds were added to the medium to determine inhibition of forskolin-stimulated adenylate cyclase.

The compounds of the present invention, in addition to having activity as a serotonin agonist also possess tachykinin receptor activity. The biological efficacy of a compound believed to be effective as a tachykinin receptor antagonist may be confirmed by employing an initial screening assay which rapidly and accurately measured the binding of the tested compound to known NK-1 and NK-2 receptor sites. Assays useful for evaluating tachykinin receptor antagonists are well known in the art. See, e.g., J. Jukic, et al., Life Sciences, 49:1463-1469 (1991); N. Kucharczyk, et al., Journal of Medicinal Chemistry, 36:1654-1661 (1993); N. Rouissi, et al., Biochemical and Biophysical Research Communications, 176:894-901 (1991).

NK-1 Receptor Binding Assay

Radioreceptor binding assays were performed using a derivative of a previously published protocol. D.G. Payan, et al., Journal of Immunology, 133:3260-3265 (1984). In this assay an aliquot of IM9 cells (1×10^6 cells/tube in RPMI 1604 medium supplemented with 10% fetal calf serum) was incubated with 20 pM ^{125}I -labeled substance P in the presence of increasing competitor concentrations for 45 minutes at 4°C.

- 52 -

The IM9 cell line is a well-characterized cell line which is readily available to the public. See, e.g., Annals of the New York Academy of Science, 190: 221-234 (1972); Nature (London), 251:443-444 (1974); Proceedings of the National Academy of Sciences (USA), 71:84-88 (1974). These cells were routinely cultured in RPMI 1640 supplemented with 50 µg/ml gentamicin sulfate and 10% fetal calf serum.

The reaction was terminated by filtration through a glass fiber filter harvesting system using filters previously soaked for 20 minutes in 0.1% polyethylenimine. Specific binding of labeled substance P was determined in the presence of 20 nM unlabeled ligand.

Many of the compounds employed in the methods of the present invention are also effective antagonists of the NK-2 receptor.

NK-2 Receptor Binding Assay

The CHO-hNK-2R cells, a CHO-derived cell line transformed with the human NK-2 receptor, expressing about 400,000 such receptors per cell, were grown in 75 cm² flasks or roller bottles in minimal essential medium (alpha modification) with 10% fetal bovine serum. The gene sequence of the human NK-2 receptor is given in N.P. Gerard, et al., Journal of Biological Chemistry, 265:20455-20462 (1990).

For preparation of membranes, 30 confluent roller bottle cultures were dissociated by washing each roller bottle with 10 ml of Dulbecco's phosphate buffered saline (PBS) without calcium and magnesium, followed by addition of 10 ml of enzyme-free cell dissociation solution (PBS-based, from Specialty Media, Inc.). After an additional 15 minutes, the dissociated cells were pooled and centrifuged at 1,000 RPM for 10 minutes in a clinical centrifuge. Membranes were prepared by homogenization of the cell pellets in 300 ml 50 mM Tris buffer, pH 7.4 with a Tekmar[®] homogenizer for 10-15 seconds, followed by centrifugation at 12,000 RPM (20,000 x g) for 30 minutes using a Beckman JA-14[®] rotor. The pellets were washed once using the above procedure. and the final pellets were resuspended in 100-120 ml 50 mM Tris buffer, pH 7.4, and 4

- 53 -

ml aliquots stored frozen at -70°C . The protein concentration of this preparation was 2 mg/ml.

For the receptor binding assay, one 4-ml aliquot of the CHO-hNK-2R membrane preparation was suspended in 40 ml of assay buffer containing 50 mM Tris, pH 7.4, 3 mM manganese chloride, 0.02% bovine serum albumin (BSA) and 4 $\mu\text{g/ml}$ chymostatin. A 200 μl volume of the homogenate (40 μg protein) was used per sample. The radioactive ligand was [^{125}I]iodohistidyl-neurokinin A (New England Nuclear, NEX-252), 2200 Ci/mmol. The ligand was prepared in assay buffer at 20 nCi per 100 μl ; the final concentration in the assay was 20 pM. Non-specific binding was determined using 1 μM eledoisin. Ten concentrations of eledoisin from 0.1 to 1000 nM were used for a standard concentration-response curve.

All samples and standards were added to the incubation in 10 μl dimethylsulfoxide (DMSO) for screening (single dose) or in 5 μl DMSO for IC_{50} determinations. The order of additions for incubation was 190 or 195 μl assay buffer, 200 μl homogenate, 10 or 5 μl sample in DMSO, 100 μl radioactive ligand. The samples were incubated 1 hr at room temperature and then filtered on a cell harvester through filters which had been presoaked for two hours in 50 mM Tris buffer, pH 7.7, containing 0.5% BSA. The filter was washed 3 times with approximately 3 ml of cold 50 mM Tris buffer, pH 7.7. The filter circles were then punched into 12 x 75 mm polystyrene tubes and counted in a gamma counter.

The compounds of the present invention have demonstrated efficacy as both tachykinin receptor antagonists and serotonin agonists. The especially preferred methods of the present invention are those methods treating conditions in which the synergistic combination of tachykinin receptor antagonists and serotonin agonists are recognized.

Animal and human clinical models demonstrating the effectiveness of the methods of the present invention are well known to those skilled in the art. For example, the following experiment clearly demonstrates the inhibitory effect of the compounds of the present invention on an animal model predictive of migraine therapies.

Neurogenic Plasma Estravasation in the Dural Layer Induced by
Electrical Stimulation

5 Harlan Sprague-Dawley rats (225-325 g) or guinea pigs from
Charles River Laboratories (225-325 g) were anesthetized with sodium
phenobarbital (65 mg/kg or 45 mg/kg, respectively, intraperitoneally) and
placed in a stereotaxic frame (David Kopf Instruments) with the incisor
bar set at -3.5 mm for rats or -4.0 mm for guinea pigs. Following a
10 midline sagittal scalp incision, two pairs of bilateral holes were drilled
through the skull (6 mm posteriorly, 2.0 and 4.0 mm laterally for rats; 4
mm posteriorly and 3.2 and 5.2 mm laterally for guinea pigs -- all
coordinates reference to bregma). Pairs of stainless steel stimulating
electrodes, insulated except for the tips, were lowered through the holes in
15 both hemispheres to a depth of 9 mm (rats) or 10.5 mm (guinea pigs) from
dura.

The femoral vein was exposed and a dose of the test
compound was injected intravenously (1 ml/kg). Approximately seven
minutes later, a 50 mg/kg dose of Evans Blue, a fluorescent dye, was also
20 injected intravenously. The Evans Blue complexed with proteins in the
blood and functioned as a marker for protein extravasation. Exactly ten
minutes post-injection of the test compound, the left trigeminal ganglion
was stimulated for three minutes at a current intensity of 1.0 mA (5 Hz, 4
msec duration) with a potentiostat/galvanostat.

25 Fifteen minutes following the stimulation, the animals were
killed and exanguinated with 20 ml of saline. The top of the skull was
removed to facilitate the collection of the dural membranes. The
membrane samples were removed from both hemispheres, rinsed with
water, and spread flat on microscopic slides. Once dried, the tissues were
30 coverslipped with a 70% glycerol/water solution.

A fluorescence microscope equipped with a grating
monochromator and a spectrophotometer was used to quantify the amount
of Evans Blue dye in each tissue sample. An excitation wavelength of
approximately 535 nm was utilized and the emission intensity at 600 nm
35 was determined. The microscope was equipped with a motorized stage

- 55 -

and was interfaced with a personal computer. This facilitated the computer-controlled movement of the stage with fluorescence measurements at 25 points (500 μm steps) on each dural sample. The mean and standard deviation of the measurements were determined by the computer.

The dural extravasation induced by electrical stimulation of the trigeminal ganglion was an ipsilateral effect (i.e. it occurs only on the side of the dura in which the trigeminal ganglion was stimulated). This allowed the other, unstimulated, half of the dura to be used as a control. The ratio of the amount of extravasation in the dura from the stimulated side compared to the unstimulated side was calculated. Saline controls yielded a ratio of approximately 2.0 in rats and 1.8 in guinea pigs. In contrast, a compound which effectively prevented the extravasation in the dura from the stimulated side would have a ratio of approximately 1.0. A dose-response curve was generated and the dose that inhibited the extravasation by 50% (ID_{50}) was estimated.

Numerous recent publications have demonstrated that migraine and numerous psychiatric disorders are co-morbid. Individuals with migraine are at a higher risk of developing these disorders, which are described in detail *infra*. N. Breslau, *et al.*, Headache, 34:387-393 (1994); K.R. Merikangas, *et al.*, Archives of General Psychiatry, 47:849-853 (1990); N. Breslau, *et al.*, Psychiatry Research, 37:11-23 (1991); W.F. Stewart, *et al.*, Psychosom. Medicine, 51:559-569; J. Jarman, *et al.*, Journal of Neurological and Neurosurgical Psychiatry, 53:573-575 (1990); V. Glover, *et al.*, Journal of Psychiatric Research, 27:223-231 (1993); N. Breslau and G.C. Davis, Journal of Psychiatric Research, 27:211-221 (1993); and K.R. Merikangas, *et al.*, Journal of Psychiatric Research, 27:197-210 (1993). This invention describes the co-morbidity of migraine pain and other pains such as those exemplified herein.

Co-pending United States Patent Application 08/318,330, filed October 5, 1994, clearly demonstrates that those compounds having an affinity for the 5-HT_{1F} receptor subtype are most advantageous for the treatment of migraine. Co-pending United States Patent Application Serial Number 08/318,391, filed October 5, 1994, clearly demonstrates

- 56 -

that a combination of a serotonin agonist and a tachykinin receptor antagonist are superior to either class of compound alone in the treatment of migraine, the combination demonstrating a synergistic efficacy profile.

5 The advantages of any synergistic combination therapy are obvious. Among its other advantages, this combination therapy greatly increases the therapeutic index of a composition in treating these nociceptive disorders. A markedly decreased amount of a serotonin agonist may now be administered to a patient, presumably greatly lessening the likelihood and severity of any adverse events. The reduced
10 amount of active ingredient necessary for a therapeutic effect makes possible other routes of formulation than those currently employed. Rapid onset formulations such as buccal or sublingual may now be developed. Sustained release formulations are now more feasible due to the lower amounts of active ingredient necessary.

15 The methods of the present invention are particularly advantageous in the treatment or prevention of pain. These methods are especially preferred in the treatment or prevention of types of pain generally considered refractory to standard non-sedating, non-addictive
20 therapies. Such pains include chronic pain, such as neuropathic pain, and post-operative pain, pain associated with arthritis, cancer-associated pain, chronic lower back pain, cluster headaches, herpes neuralgia, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and
25 delivery, pain resulting from burns, including sunburn, post partum pain, angina pain, and genitourinary tract-related pain including cystitis.

Animal and human clinical models demonstrating the effectiveness of the compounds of the present invention in treating
30 psychiatric disorders are well known to those skilled in the art. For example, in evaluating the methods of the present invention in treating or preventing anxiety the following models may be employed.

Punished Responding

35

- 57 -

The antianxiety activity of the compositions employed in the method of the present invention is established by demonstrating that these compositions increase punished responding. This procedure has been used to establish antianxiety activity in clinically established compositions.

According to this procedure, the responding of rats or pigeons is maintained by a multiple schedule of food presentation. In one component of the schedule, responding produces food pellet presentation only. In a second component, responding produces both food pellet presentation and is also punished by presentation of a brief electric shock. Each component of the multiple schedule is approximately 4 minutes in duration, and the shock duration is approximately 0.3 seconds. The shock intensity is adjusted for each individual animal so that the rate of punished responding is approximately 15 to 30% of the rate in the unpunished component of the multiple schedule. Sessions are conducted each weekday and are approximately 60 minutes in duration. Vehicle or a dose of composition are administered 30 minutes to 6 hours before the start of the test session by the subcutaneous or oral route. Composition effects for each dose for each animal are calculated as a percent of the vehicle control data for that animal. The data are expressed as the mean \pm the standard error of the mean.

Monkey Taming Model

The antianxiety activity of the compositions is established by demonstrating that the compositions are effective in the monkey taming model. Plotnikoff, Res. Comm. Chem. Path. & Pharmacol., 5:128-134 (1973) describes the response of rhesus monkeys to pole prodding as a method of evaluating the antiaggressive activity of a test composition. In this method, the antiaggressive activity of a composition is considered to be indicative of its antianxiety activity. Hypoactivity and ataxia are considered to be indicative of a sedative component of the composition. The present study is designed to measure the pole prod response-inhibition induced by a composition of this invention in comparison with that of a standard antianxiety composition employing a compound such as

- 58 -

diazepam as a measure of antiaggressive potential, and to obtain an indication of the duration of action of the compound.

5 Male and female rhesus or cynomologous monkeys, selected for their aggressiveness toward a pole, are housed individually in a primate colony room. Compositions or appropriate vehicle are administered orally or subcutaneously and the animals are observed by a trained observer at varying times after drug administration. A minimum of three days (usually a week or more) elapses between treatments. Treatments are assigned in random fashion except that no monkey
10 receives the same composition two times consecutively.

Aggressiveness and motor impairment are graded by response to a pole being introduced into the cage as described in Table II. The individuals responsible for grading the responses are unaware of the dose levels received by the monkeys.
15

- 59 -

Table II

Grading of Monkey Response to Pole Introduction

	<u>Response</u>	<u>Grade</u>	<u>Description</u>
5	Attack	2	Monkey immediately grabbed and/or bit pole as it was placed at opening in cage.
10		1	Monkey grabbed and/or bit pole only after the tip was extended into the cage 12 inches or more.
		0	No grabbing or biting observed.
	Pole Push	2	Monkey grabbed the pole to attack it or push it away.
15		1	Monkey touched the pole only in attempting to avoid it or rode on the pole (avoidance).
		0	No pushing, grabbing or riding of the pole observed.
20	Biting	2	Monkey bit aggressively and frequently.
		1	Monkey bit weakly or infrequently
		0	No biting observed.
25	Ataxia	2	Monkey exhibited a marked loss of coordination.
		1	Slight loss of coordination observed.
		0	No effects on coordination observed.
30	Hypoactivity	2	Marked: Monkey was observed in a prone position. May or may not have responded by rising and moving away when experimenter approached.
		1	Slight: Monkey did not retreat as readily when experimenter approached
		0	None.

- 60 -

Antiaggression Activity of Drug Dose

- + Dose of drug was active in decreasing global assessment of aggressive behavior
- Dose of drug was not active in decreasing aggressive behavior

Human Clinical Trials

5 Finally, the antianxiety activity of the named compositions and methods can be demonstrated by human clinical trials. The study is designed as a double-blind, parallel, placebo-controlled multicenter trial. The patients are randomized into four groups, placebo and 25, 50, and 75 mg tid of test composition. The dosages are administered orally with food.
10 Patients are observed at four visits to provide baseline measurements. Visits 5-33 served as the treatment phase for the study.

 During the visits, patients and their caregivers were questioned and observed for signs of agitation, mood swings, vocal outbursts, suspiciousness, and fearfulness. Each of these behaviors are
15 indicative of the effect of the test composition on an anxiety disorder.

 The patient to be benefited by practice of the present invention is a patient having one or more of the disorders discussed in detail below, or who is at a heightened risk of contracting such disorder.
20 Diagnosis of these disorders, or the identification of a patient at risk of one or more of them, is to be made by a physician or psychiatrist. It is presently believed that the combination of serotonin receptor agonists and tachykinin receptor antagonists results in the alleviation of the effects of the disorder from which the patient suffers, or even the elimination of the
25 disorder completely.

 A patient with a heightened risk of contracting one of the present disorders is a patient, in the present contemplation, who is more likely than is a normal person to fall victim to that disorder. The patient

- 61 -

may have suffered from the disorder in the past, and be at risk of a relapse, or may exhibit symptoms which demonstrate to the physician or psychiatrist that the patient is under an abnormal risk of developing the disorder in its full form.

5 The disorders which are treated or prevented in the practice of the present invention may be described as follows.

 bulimia nervosa
 obsessive-compulsive disorder
10 premenstrual dysphoric disorder
 substance abuse
 substance dependence
 panic disorder
 panic attack
15 agoraphobia
 post-traumatic stress disorder
 dementia of Alzheimer's type
 social phobia
 attention deficit hyperactivity disorder
20 disruptive behavior disorder
 intermittent explosive disorder
 borderline personality disorder
 chronic fatigue syndrome
 premature ejaculation
25 depression and behavioral problems associated with head
 injury, mental retardation or stroke.

 Most of the disorders discussed here are described and categorized in the DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
30 DISORDERS, (4th edition, 1994), published by the American Psychiatric Association (hereinafter referred to as DSM). In the discussion below, the DSM codes for the disorders will be given where appropriate.

 Bulimia nervosa, DSM 307.51, is characterized by uncontrollable binge eating, followed by self-induced purging, usually
35 vomiting. Its prevalence is as high as 1%-3% among adolescent and young

- 62 -

adult females. The disorder is well characterized and recognized by the health professions. The essential features of it are binge eating and inappropriate compensatory methods to prevent weight gain. Further, individuals with the disorder are excessively influenced by body shape and weight.

Obsessive-compulsive disorder, DSM 300.3, is characterized by recurrent obsessions or compulsions which are severe enough to be time consuming or cause distress or impairment of the patient's life.

Obsessions are persistent ideas, thoughts, impulses or images which are recognized by the patient to be intrusive and inappropriate and cause anxiety or distress. The individual senses that the obsession is alien, not under control and not the kind of thought that the patient would expect to have. Common obsessions include repeated thoughts about contamination, repeated doubts, a need to arrange things in a particular order, aggressive or horrific impulses and sexual imagery. Compulsions are repetitive behaviors, such as hand washing, or mental acts, such as counting or repeating words silently, the goal of which is to prevent or reduce anxiety or distress. By definition, compulsions are either clearly excessive or not realistically connected with that which they are designed to neutralize or prevent. Obsessive-compulsive disorder is rather common, with an estimated lifetime prevalence of 2.5%.

Substance abuse and substance dependence, very well known in most societies at present, come about when the patient becomes addicted or habituated to the improper use of a drug or other substance. Several different varieties of substance abuse and dependence will be discussed in detail below. It will be understood that substance abuse or dependence often results in additional disorders, including intoxication, withdrawal symptoms, delirium, psychotic disorders, hallucinations, mood disorders, anxiety disorders, sexual dysfunctions, or sleep disorders. Recognized substance abuse and substance dependence disorders which are part of the present invention include the following:

amphetamine dependence, DSM 304.40

amphetamine abuse, DSM 305.70

cannabis dependence, DSM 304.30

- 63 -

cannabis abuse, DSM 305.20
 cocaine dependence, DSM 304.20
 cocaine abuse, DSM 305.60
 hallucinogen dependence, DSM 304.50
 5 hallucinogen abuse, DSM 305.30
 inhalant dependence, DSM 304.60
 inhalant abuse, DSM 305.90
 nicotine dependence, DSM 305.10
 opioid dependence, DSM 304.00
 10 opioid abuse, DSM 305.50
 phencyclidine dependence, DSM 304.90
 phencyclidine abuse, DSM 305.90
 sedative, hypnotic or anxiolytic dependence, DSM 304.10
 sedative, hypnotic or anxiolytic abuse, DSM 305.40
 15 polysubstance dependence, DSM 304.80

The prevalence and deleterious effects of substance dependence and substance abuse are almost too well known to discuss. The disorders are characterized, in general, by a compulsion to use the substance in
 20 question in order to obtain its effects, regardless of the ill-effects of the substance or the difficulty, expense or danger of obtaining it. Some substances of abuse, such as cannabis and cocaine, have run through entire sections of society and have damaged or ruined untold numbers of lives. The importance of the ability to relieve such disorders in accordance
 25 with the present invention is obviously of great significance.

Panic attack, panic disorder and agoraphobia, categorized as DSM 300.01, 300.21 and 300.22, affect between 1.5% and 3.5% of the population. The disorders are characterized by irrational sense of
 30 imminent danger or doom, an urge to escape, or a fear of being in a situation from which escape might be difficult. The patient exhibits symptoms such as palpitations, accelerated heart rate, sweating, sensations of shortness of breath, chest pain, nausea, dizziness, fear of dying, and the like, and may have such attacks very frequently.

Social phobia, DSM 300.23, produces a marked and persistent
 35 fear of social or performance situations in which embarrassment may

- 64 -

occur. Exposure to such a situation may result in a panic attack, or other anxious response. Most often, patients with the disorder simply avoid situations of the type which they dread, producing an obvious dislocation in the patient's life. The prevalence of social phobia has been reported as
5 from 3% to 13%, on a lifetime basis.

Post-traumatic stress disorder, DSM 309.81, afflicts patients following exposure to a traumatic stress involving personal experience of an event involving actual or threatened death of injury. Such traumatic events include experiences such as military combat, personal assault,
10 kidnapping, terrorist attack, torture, natural or man-made disasters, severe accidents, or being diagnosed with a dreaded illness. Learning about such events occurring to others, particularly a family member or close friend, also may produce the disorder. Triggering events which symbolize the traumatic event, such as an anniversary, may recreate the
15 stress and bring on the disorder long after the event is passed. Patients strive to avoid stimuli associated with the trauma, even to the point of amnesia or reduced responsiveness to other people in general. Prevalence of post-traumatic stress disorder has been reported at from 1% to as much as 14%, and has been reported at 50% and more in studies of individuals
20 who are at risk of the disorder.

Dementia of the Alzheimer's type, DSM 290.11, 290.12, 290.13, 290.10, 290.3, 290.20, 290.21 and 290.0, affects between 2% and 4% of the population over 65 years old. The prevalence increases with age, particularly after 75 years of age, and is associated with Alzheimer's
25 disease. In most patients, brain atrophy or deterioration is present, and is associated with the dementia.

Attention deficit hyperactivity disorder, DSM 314.01 and 314.00, is primarily recognized as a disorder of children, but may well be found in adults as well. It is characterized by symptoms such as lack of
30 attention, impulsivity, and excessive activity, resulting in high expenditure of effort accompanied with a low degree of accomplishment. Patients have difficulty or find it impossible to give attention to details, cannot sustain attention in tasks or even play, and make careless mistakes. They fail to listen to or follow through on instructions, lose
35 things, and are easily distracted by extraneous events. The difficulty of

- 65 -

such patients in carrying out useful lives is obvious from the mere recital of the symptoms.

Disruptive behavior disorder, DSM 312.9, is a condition characterized by aggressive, destructive, deceitful and defiant activity.

5 Intermittent explosive disorder, DSM 312.34, is characterized by episodes of failure to resist aggressive impulses, resulting in assault or destruction of property. The degree of aggressiveness expressed during episodes of this disorder is grossly disproportionate to any provocation or triggering stress. The Southeastern Asian condition of amok is an episode
10 of this disorder, cases of which have been reported in Canada and the United States as well.

Borderline personality disorder, DSM 301.83, is marked by a pervasive pattern of instability of interpersonal relationships and self-image, and marked impulsivity which begins by early adulthood. Patients
15 have a pattern of unstable and intense relationships, very quickly developing a very close relationship and then quickly devaluing the other person. Patients may gamble, spend irresponsibly, binge eat, abuse substances, engage in unsafe sex or drive recklessly. Patients often display recurrent suicidal behavior or self-injurious behavior. The
20 prevalence is estimated to be about 2% of the population.

Premature ejaculation, DSM 302.75, is characterized by the inability of a male to delay orgasm as long as is desired.

Depression and behavioral problems associated with head injury, mental retardation or stroke are treated in the exercise of the
25 present invention. Such depression and behavioral problems are distinct from the usual such disorders, because of their origin. Depression, of course, of the general type is quite prevalent and is now well-known, being well treated with pharmaceuticals such as, for example, fluoxetine.

Chronic fatigue syndrome is a condition which has been
30 variously described and diagnosed. It is sometimes categorized as a low-grade viral infection, particularly caused by the Epstein-Barr virus. Since that virus is very widely found in the population, however, the diagnosis is problematic. An alternative characterization of chronic fatigue syndrome is a physical-psychological disorder of the depression type,
35 characterized primarily by lack of energy and listlessness.

- 66 -

Premenstrual dysphoric disorder is characterized by symptoms such as feelings of sadness, hopelessness or self-deprecation; anxiety or tenseness; tearfulness and lability of mood; persistent irritability and anger; decreased interest in usual activities or withdrawal from relationships; difficulty concentrating and the like. It is not classified formally by DSM but is discussed in detail there. The pattern of symptoms occurs in most cycles, frequently beginning the week prior to menses. Frequently, the disorder markedly interferes with the patient's life in all respects during the attack of the disorder. The prevalence of the disorder in its most profound form has been estimated at 3%-5%, but there has been little systematic study on the course and stability of the condition.

Animal and human clinical models demonstrating the effectiveness of the compounds of the present invention in treating the common cold or allergic rhinitis are well known to those skilled in the art. For example, in evaluating the methods of the present invention in treating or ameliorating the symptoms of the common cold or allergic rhinitis, it is especially preferred to ultimately employ clinical studies. Human clinical studies for evaluating the effectiveness of a treatment of either of these disorders are described in United States Patents 5,240,694, issued August 31, 1993, and 5,252,602, issued October 12, 1993, the entirety of which are herein incorporated by reference.

While it is possible to administer a compound employed in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one active ingredient. These compositions can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. See, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed. 1980).

- 67 -

In making the compositions employed in the present invention the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves
5 as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for
10 example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to
15 combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

20 Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include:
25 lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient
30 after administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active ingredient. The term "unit
35 dosage form" refers to physically discrete units suitable as unitary dosages

- 68 -

for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

5 The active compounds are generally effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight. In the treatment of adult humans, the range of about 0.1 to about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that
10 the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and
15 therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several
20 smaller doses for administration throughout the day.

Formulation Preparation 1

25 Hard gelatin capsules containing the following ingredients are prepared:

<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
Active Ingredient	30.0
30 Starch	305.0
Magnesium stearate	5.0

- 69 -

The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

Formulation Preparation 2

5

A tablet formula is prepared using the ingredients below:

<u>Ingredient</u>	<u>Quantity (mg/tablet)</u>
10 Active Ingredient	25.0
Cellulose, microcrystalline	200.0
Colloidal silicon dioxide	10.0
15 Stearic acid 5.0	

The components are blended and compressed to form tablets, each weighing 240 mg.

20

Formulation Preparation 3

A dry powder inhaler formulation is prepared containing the following components:

25

<u>Ingredient</u>	<u>Weight %</u>
Active Ingredient	5
Lactose	95

30

The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

- 70 -

Formulation Preparation 4

Tablets, each containing 30 mg of active ingredient, are prepared as follows:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/tablet)</u>
5	Active Ingredient	30.0 mg
10	Starch	45.0 mg
	Microcrystalline cellulose	35.0 mg
15	Polyvinylpyrrolidone (as 10% solution in water)	4.0 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
20	Talc	<u>1.0 mg</u>
	Total	120 mg

25 The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve. The sodium
30 carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.

- 71 -

Formulation Preparation 5

Capsules, each containing 40 mg of medicament are made as follows:

	<u>Quantity</u> <u>(mg/capsule)</u>
5	
<u>Ingredient</u>	
Active Ingredient	40.0 mg
10 Starch	109.0 mg
Magnesium stearate	<u>1.0 mg</u>
Total	150.0 mg

15

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

20

Formulation Preparation 6

Suppositories, each containing 25 mg of active ingredient are made as follows:

	<u>Amount</u>
25	
<u>Ingredient</u>	
Active Ingredient	25 mg
Saturated fatty acid glycerides to	2,000 mg

30

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

- 72 -

Formulation Preparation 7

5 Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

	<u>Ingredient</u>	<u>Amount</u>
	Active Ingredient	50.0 mg
10	Xanthan gum	4.0 mg
	Sodium carboxymethyl cellulose (11%) Microcrystalline cellulose (89%)	50.0 mg
15	Sucrose	1.75 g
	Sodium benzoate	10.0 mg
	Flavor and Color	q.v.
20	Purified water to	5.0 ml

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a
25 previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

- 73 -

Formulation Preparation 8

5 Capsules, each containing 15 mg of medicament, are made as follows:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
10	Active Ingredient	15.0 mg
	Starch	407.0 mg
	Magnesium stearate	<u>3.0 mg</u>
15	Total	425.0 mg

20 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.

Formulation Preparation 9

An intravenous formulation may be prepared as follows:

	<u>Ingredient</u>	<u>Quantity</u>
25	Active Ingredient	250.0 mg
30	Isotonic saline	1000 ml

- 74 -

Formulation Preparation 10

A topical formulation may be prepared as follows:

	<u>Ingredient</u>	<u>Quantity</u>
5	Active Ingredient	1-10 g
	Emulsifying Wax	30 g
10	Liquid Paraffin	20 g
	White Soft Paraffin	to 100 g

15 The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

- 75 -

Formulation Preparation 11

Sublingual or buccal tablets, each containing 10 mg of active ingredient, may be prepared as follows:

<u>Ingredient</u>	<u>Quantity Per Tablet</u>
Active Ingredient	10.0 mg
10 Glycerol	210.5 mg
Water	143.0 mg
Sodium Citrate	4.5 mg
15 Polyvinyl Alcohol	26.5 mg
Polyvinylpyrrolidone	<u>15.5 mg</u>
Total	410.0 mg

20 The glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90°C. When the polymers have gone into solution, the solution is cooled to about 50-55°C and the
 25 medicament is slowly admixed. The homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.

30 Another preferred formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for
 35 the delivery of pharmaceutical agents is well known in the art. See, e.g.,

- 76 -

U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

5 Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S.
10 Patent 5,011,472, issued April 30, 1991, which is herein incorporated by reference.


Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs.
15 Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can
20 transiently open the blood-brain barrier.

The type of formulation employed for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compounds employed, the type of
25 pharmacokinetic profile desired from the route of administration and the compound, and the state of the patient.

- 77 -

We Claim:

1. A method of treating a condition associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of the formula



wherein:

10

R^1 , R^2 , and R^3 are independently hydrogen, halo, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, nitro, trifluoromethyl, or C_1 - C_6 alkyl;

15

A is $-CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$;

R^a is hydrogen or hydroxy, and R^b is hydrogen, or R^a and R^b are taken together to form a bond;

20

R^4 and R^5 are independently taken from the group consisting of halo, trifluoromethyl, hydrogen, C_1 - C_6 alkoxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 alkylamino, hydroxy, cyano, C_2 - C_7 alkanoyl, C_2 - C_7 alkanoyloxy, benzamido, phenoxy, benzyloxy,

- 78 -

carboxamido, hydroxy, phenyl(C₂-C₇ alkanoyl)-, phenyl(C₂-C₇ carbamoyl)-,

5 said benzamido, phenoxy, benzyloxy, phenyl(C₂-C₇ alkanoyl)-, and phenyl(C₂-C₇ carbamoyl)-
being optionally substituted with one or more
groups selected from the group consisting of
halo, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy,
cyano, hydroxy, amino and nitro;

10

or a pharmaceutically acceptable salt or solvate thereof.

2. A method as claimed in **Claim 1** employing a
compound wherein A is methylenyl, or ethylenyl.

15

3. A method as claimed in **Claim 2** employing a
compound wherein R¹, R², and R³ are independently hydrogen, chloro,
fluoro, bromo, methoxy, ethoxy, trifluoromethyl, methyl, ethyl or
isopropyl.

20

4. A method as claimed in **Claim 3** employing a
compound wherein at least one of R¹, R², and R³ is hydrogen.


5. A method as claimed in **Claim 4** employing (R)-2-{{4-
25 [5-(chloro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-
indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-
(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-
yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(4-
fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-
30 acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(chloro)indol-3-
yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-
yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
35 methoxybenzyl)propanamine, (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-
tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-

- 79 -

methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine or (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, or a pharmaceutically acceptable salt or solvate thereof.

10

6. A compound of the formula



wherein:

15

R^1 , R^2 , and R^3 are independently hydrogen, halo, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, nitro, trifluoromethyl, or C_1 - C_6 alkyl;

A is $-CH_2-$, $-CH_2CH_2-$, or $-CH_2CH_2CH_2-$;

20

R^a is hydrogen or hydroxy, and R^b is hydrogen, or R^a and R^b are taken together to form a bond;

- 80 -

5 R⁴ and R⁵ are independently taken from the group consisting of halo, trifluoromethyl, hydrogen, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₁-C₆ alkylthio, C₁-C₆ alkylamino, hydroxy, cyano, C₂-C₇ alkanoyl, C₂-C₇ alkanoyloxy, benzamido, phenoxy, benzyloxy, carboxamido, hydroxy, phenyl(C₂-C₇ alkanoyl)-, phenyl(C₂-C₇ carbamoyl)-,

10 said benzamido, phenoxy, benzyloxy, phenyl(C₂-C₇ alkanoyl)-, and phenyl(C₂-C₇ carbamoyl)- being optionally substituted with one or more groups selected from the group consisting of halo, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, cyano, hydroxy, amino and nitro;

15 or a pharmaceutically acceptable salt or solvate thereof.

7. A compound as claimed in **Claim 6** wherein A is methylenyl, or ethylenyl.

20 8. A compound as claimed in **Claim 7** wherein R¹, R², and R³ are independently hydrogen, chloro, fluoro, bromo, methoxy, ethoxy, trifluoromethyl, methyl, ethyl or isopropyl.

25 9. A compound as claimed in **Claim 8** wherein at least one of R¹, R², and R³ is hydrogen.


30 10. A compound as claimed in **Claim 9** selected from the group consisting of (R)-2-{{4-[5-(chloro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-

35

- 81 -

methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine and (R)-2-{{4-[5-
 10 [(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, or a pharmaceutically acceptable salt or solvate thereof.

15 11. A pharmaceutical formulation comprising a compound of the formula



20 wherein:

R¹, R², and R³ are independently hydrogen, halo, C₁-C₆ alkoxy, C₁-C₆ alkylthio, nitro, trifluoromethyl, or C₁-C₆ alkyl;

- 82 -

A is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{CH}_2-$;

5 R^a is hydrogen or hydroxy, and R^b is hydrogen, or R^a and R^b are taken together to form a bond;

10 R^4 and R^5 are independently taken from the group consisting of halo, trifluoromethyl, hydrogen, C_1 - C_6 alkoxy, C_1 - C_6 alkyl, C_1 - C_6 alkylthio, C_1 - C_6 alkylamino, hydroxy, cyano, C_2 - C_7 alkanoyl, C_2 - C_7 alkanoyloxy, benzamido, phenoxy, benzyloxy, carboxamido, hydroxy, phenyl(C_2 - C_7 alkanoyl)-, C_1 - C_6 phenyl(C_2 - C_7 carbamoyl)-,

15 said benzamido, phenoxy, benzyloxy, phenyl(C_2 - C_7 alkanoyl)-, and phenyl(C_2 - C_7 carbamoyl)- being optionally substituted with one or more groups selected from the group consisting of halo, trifluoromethyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, cyano, hydroxy, amino and nitro;

20 or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients therefor.

25 12. A formulation as claimed in Claim 11 employing a compound wherein A is methylenyl, or ethylenyl.

30 13. A formulation as claimed in Claim 12 employing a compound wherein R^1 , R^2 , and R^3 are independently hydrogen, chloro, fluoro, bromo, methoxy, ethoxy, trifluoromethyl, methyl, ethyl or isopropyl.


35 14. A formulation as claimed in Claim 13 employing a compound wherein at least one of R^1 , R^2 , and R^3 is hydrogen.

- 83 -

15. A formulation as claimed in Claim 14 employing (R)-
2-{{4-[5-(chloro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-
(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-
(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-
5 yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(4-
fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-
acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(chloro)indol-3-
yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-
10 yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine, (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-
tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-
tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
15 methoxybenzyl)propanamine, (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-
yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-
methoxybenzyl)propanamine or (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-
3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-
N-(2-methoxybenzyl)propanamine, or a pharmaceutically acceptable salt
20 or solvate thereof.

16. A method of treating a condition associated with an
inappropriate modulation of a serotonin receptor which comprises
administering to a mammal in need thereof an effective amount of a
25 compound of the formula

- 84 -



wherein:

5 R¹, R², and R³ are independently hydrogen, halo, C₁-C₆ alkoxy, C₁-C₆ alkylthio, nitro, trifluoromethyl, or C₁-C₆ alkyl;

A is -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂-;

10 R^a is hydrogen or hydroxy, and R^b is hydrogen, or R^a and R^b are taken together to form a bond;

15 R⁴ and R⁵ are independently taken from the group consisting of halo, trifluoromethyl, hydrogen, C₁-C₆ alkoxy, C₁-C₆ alkyl, C₁-C₆ alkylthio, C₁-C₆ alkylamino, hydroxy, cyano, C₂-C₇ alkanoyl, C₂-C₇ alkanoyloxy, benzamido, phenoxy, benzyloxy, carboxamido, hydroxy, phenyl(C₂-C₇ alkanoyl)-, phenyl(C₂-C₇ carbamoyl)-,

20 said benzamido, phenoxy, benzyloxy, phenyl(C₂-C₇ alkanoyl)-, and phenyl(C₂-C₇ carbamoyl)- being optionally substituted with one or more

- 85 -

groups selected from the group consisting of halo, trifluoromethyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, cyano, hydroxy, amino and nitro;

5 or a pharmaceutically acceptable salt or solvate thereof.

17. A method as claimed in **Claim 16** employing a compound wherein A is methylenyl, or ethylenyl.

10 18. A method as claimed in **Claim 17** employing a compound wherein R¹, R², and R³ are independently hydrogen, chloro, fluoro, bromo, methoxy, ethoxy, trifluoromethyl, methyl, ethyl or isopropyl.

15 19. A method as claimed in **Claim 18** employing a compound wherein at least one of R¹, R², and R³ is hydrogen.

20 20. A method as claimed in **Claim 19** employing (R)-2-{{4-[5-(chloro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(cyano)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(4-fluorobenzamido)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(chloro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(methoxy)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(fluoro)indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine, (R)-2-{{4-[5-(hydroxy)indol-3-yl]piperidin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-N-(2-methoxybenzyl)propanamine or (R)-2-{{4-[5-[(benzylamino)carbonyl]indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl]acetamido}-3-(1H-indol-3-yl)-N-acetyl-

25
30
35

- 86 -

N-(2-methoxybenzyl)propanamine, or a pharmaceutically acceptable salt or solvate thereof.

5 21. A compound as claimed in any one of **Claims 11 to 15** for use in treating a condition associated with an excess of tachykinins.

 22. A compound as claimed in any one of **Claims 11 to 15** for treating a condition associated with an inappropriate stimulation of a serotonin receptor.

10

 23. The use of a compound as claimed in any one of **Claims 11 to 15** for the manufacture of a medicament.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05996

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/40, 31/55, 31/445; CO7D 209/08, 209/12, 223/04, 401/14
US CL : 514/212, 323, 414; 540/610; 546/201; 548/455

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/212, 323, 414; 540/610; 546/201; 548/455

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,328,927 A (LEWIS et al) 12 July 1994, column 4; column 14, lines 57-68.	1-15, 21, 23
A	WO 95/14017 A1 (ELI LILLY AND COMPANY) 26 May 1995, pages 3-6; page 59.	1-15, 21, 23
A, P	US 5,565,568 A (CHO ET AL) 15 October 1996, columns 2-3; column 31, lines 5-23.	1-15, 21, 23
A	US 5,328,922 A (FORBES et al) 12 July 1994, column 1.	16-20, 22
A	BOCKAERT et al. The 5-HT ₄ receptor: a place in the sun. TIPS Reviews. April 1992, Vol. 13, pages 141-145, especially page 143.	16-20, 22

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 JULY 1997

Date of mailing of the international search report

28 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

EVELYN HUANG

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05996

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05996

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-15, 21, 23, drawn to the bisindole compound, its composition and the method of using the compound for treating tachykinin-mediated conditions.

Group II, claim(s) 16-20, 22, drawn to an alternate method of using the bisindole compound for treating serotonin-mediated conditions.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: since the tachykinin receptor and the serotonin receptor are distinct from one another, the conditions associated with each are distinctly different. The method of using a compound to treat tachykinin-mediated conditions and the method of using the same compound to treat serotonin-mediated conditions therefore do not have the same or corresponding special features to form a single inventive concept. 37 CFR 1.475(d).